Arblast USA
I would like to talk about Alblast USA's patent rights based on discussions with American lawyers and the FBI.
Alblast USA is an American company and has already been listed as a reverse merger with Fortisel Bioscience, so based on the transfer agreement, Alblast's patent rights are assigned to the patent list. All patents listed in the certificate have been assigned to Alblast USA.
This will not be changed under the contract, even if Alblast filed for bankruptcy, as long as the reverse merger was successful.
Regarding this matter, Kitagawa has already explained to us as a contractual matter regarding the memorandum of understanding signed between Alblast and Shigeru Kinoshita many times.
It is also clearly stated in the following email. Relying on the content of this email and all the words of Kitagawa, Alblast USA was founded and has invested time and money to carry out the reverse merger listing.
Ryan
About the 201 patent.
The applicants for the above patents, pending patents, and their divisional patents are Alblast, and will not lose their status unless the company is reorganized or goes bankrupt. However, when licensing or assigning to a third party, the written permission of the inventor, Mr. Shigeru Kinoshita, is required. It is a clause added to prevent the transfer when it is acquired for a purpose other than commercialization, such as when it is acquired for the purpose of preventing development, and Alblast himself or a third party It is not a provision aimed at irrationally hindering the act of cooperating in commercializing the product. Therefore, as long as the Company intends to commercialize it based on the patent, its position will be secured.
_ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ /
_ / All Kitagawa Akira Kitagawa, Ph.D.
_ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ /
If it weren't for all of Kitagawa's explanations above, of course, he wouldn't undertake Reverse Marr or conclude a business transfer agreement with Alblast.
I decided to carry out the reverse merger by believing in the following 3 items listed in this mail above + 4 items that all Kitagawa told us.
1. The applicants for the above patents, pending patents, and their divisional patents are Alblast, and will not lose their status unless the company is reorganized or goes bankrupt. If the business transfer is decided at a general meeting of shareholders or the board of directors before bankruptcy and the business is transferred, the rights will be transferred to the company to which the business was transferred.
2. When licensing or assigning to a third party, the written permission of the inventor, Shigeru Kinoshita, is required. It is a clause added to prevent the transfer when it is acquired for a purpose other than commercialization, such as when it is acquired for the purpose of preventing the development of competing products. It is not a clause that aims to prevent Shigeru Kinoshita from irrationally hindering the act of commercializing the product in cooperation with a person.
3. Therefore, as long as the Company intends to commercialize it based on the patent, its position will be secured, and Shigeru Kinoshita has no right to impede it.
4. Shigeru Kinoshita, who spends about 2 billion yen worth of investment, has no right to prevent reverse mergers.
Despite this, it is natural that the actions of Shigeru Kinoshita, Zen Kitagawa, and Motohiro Kasahara, a lawyer who changed the name of the patent without permission, are crimes in the United States.
Moreover, Germany was the first to change the name of Kinoshita et al., But this change of name in Germany was several months before Alblast's bankruptcy filing, and it is not allowed.
No matter how Shigeru Kinoshita makes excuses, Alblast USA's patent has been assigned to Alblast USA, which had already succeeded in reverse marriage, under a transfer agreement.
In other words, it is not permissible in the United States to change the name of a transferred patent without permission from Alblast USA.